Antagonist anti-CD40 antibody pharmaceutical compositions
US8945564B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Apr 17, 2007 |
| Grant date | Feb 3, 2015 |
| Priority date | — |
| Expiry date | Jan 13, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody-containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.